GlassScriptPhysician profile
Hugh W Bailey
NPI 1649212358
$1,372.04
in general payments reported to CMS, 2019-2025
27 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $163 · 2021: $208 · 2022: $449 · 2023: $187 · 2024: $79.61 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $152.62 | 2021-2022 | |
| Allergan, INC. | $148.15 | 2022 | |
| Novo Nordisk INC | $123.96 | 2020-2022 | |
| Hologic Sales and Service, LLC | $101.14 | 2019-2021 | |
| Becton, Dickinson and Company | $97.60 | 2022-2023 | Bd Onclarity |
| Abbvie INC. | $85.46 | 2019-2022 | |
| Shield Therapeutics INC | $80.62 | 2022-2024 | Accrufer |
| Daiichi Sankyo INC. | $60.51 | 2019-2022 | |
| Pfizer INC. | $55.86 | 2021-2025 | |
| Organon LLC | $55.01 | 2023-2025 | Jada System |
| Scynexis, INC. | $52.57 | 2022 | |
| Coopersurgical, INC. | $37.39 | 2025 | Endosee, Paragard T 380a |
| Astellas Pharma US INC | $33.10 | 2023-2024 | Veozah |
| Currax Pharmaceuticals LLC | $29.54 | 2021 | |
| Mylan Pharmaceuticals INC. | $29.32 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $25.93 | 2025 | Zurzuvae |
| Axonics, INC. | $25.16 | 2024 | Axonics |
| Integra Lifesciences Corporation | $21.64 | 2020 | |
| Sumitomo Pharma America, INC. | $21.11 | 2024 | Gemtesa |
| Boston Scientific Corporation | $20.55 | 2019 | |
| Mayne Pharma Commercial LLC | $20.42 | 2022 | |
| Exeltis, USA INC. | $19.36 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.90 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.24 | 2025 | |
| Amag Pharmaceuticals, INC. | $14.85 | 2019 | |
| Minerva Surgical, INC | $13.75 | 2025 | |
| Lupin INC. | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugh Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.